? Deciphera $DCPH has scooped Agios’ chief commercial officer Steve Hoerter to fill retiring CEO Michael Taylor’s shoes. The Waltham, MA-based biotech is placing its trust in Hoerter’s sales acumen, especially for cancer drugs, acquired throughout his career at companies like Clovis, Roche, Genentech, Chiron, and Eli Lilly. The first Phase III trial of ripretinib, in gastrointestinal tumors, is due to read out soon.
? Having built out a commercial footprint in the US and led the launch of Bavencio for Merck KGaA, David Trexler is taking up a new role as president of German biotech Morphosys’ US subsidiary. Following a dual listing on the Nasdaq $MOR last year, Mor… […]
? France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official title will be EVP and general manager … […]
? Having handed off troubled microcap biotech Apricus Biosciences to Seelos Therapeutics via a merger, Richard Pascoe is moving on to his next CEO (and chairman) gig at Histogen. The regenerative medicine developer is anticipating data f… […]